Amgen/TKT EPO
Executive Summary
Trial set for May 15 in EPO patent dispute. Amgen claims TKT's gene-activated erythropoietin infringes its Epogen patents (1"The Pink Sheet" April 3, p. 7). Judge William Young will hear the case in Boston federal court